New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:29 EDTATNM, ESPR, TGTX, ZIOP, KBIO, HZNP, EBIO, OMER, FPRX, RGDO, DRNABioCentury to hold a conference
Future Leaders in the Biotech Industry Conference is being held in New York on March 28.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
07:16 EDTOMERAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
October 17, 2014
16:22 EDTTGTXRA Capital reports 8.3% passive stake in TG Therapeutics
10:32 EDTFPRXFive Prime management to meet with Oppenheimer
Meetings to be held in Denver on October 22 and in Chicago on October 23 hosted by Oppenheimer.
07:45 EDTHZNPHorizon Pharma to host conference call
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma acquires U.S. rights to PENNSAID 2% for $45M
Subscribe for More Information
October 16, 2014
09:23 EDTESPROn The Fly: Pre-market Movers
Subscribe for More Information
October 15, 2014
20:02 EDTESPREsperion 4.25M share Secondary priced at $20.00
JPMorgan and BofA/Merrill acted as joint book running managers for the offering.
07:32 EDTATNMRedChip Companies to hold a virtual conference
Subscribe for More Information
October 14, 2014
16:06 EDTESPREsperion files to sell $85M in common stock
Subscribe for More Information
06:00 EDTATNMActinium Pharmaceuticals management to meet with UBS
Meeting to be held in San Francisco/Los Angeles will be held on October 14 hosted by UBS.
October 13, 2014
17:06 EDTHZNPHorizon Pharma: Actimmune net sales potential $500M with FDA approval for FA
Subscribe for More Information
05:31 EDTHZNPHorizon Pharma to host analyst day
Analyst Day to be held in King of Prussia, PA on October 13 at 5 pm. Webcast Link
October 10, 2014
07:31 EDTRGDORegado Biosciences appoints Michael Metzger CEO
Regado Biosciences announced the appointment of Michael Metzger, President of Regado, to the additional post of CEO and as a member of the board effective immediately. Metzger previously served as president and chief operating officer of Regado. He replaces David Mazzo, who has resigned from the company.
October 9, 2014
15:31 EDTHZNPHorizon Pharma's Actimmune Phase 2 results provide more growth, says Avondale
Avondale said Horizon Pharma's Actimmune Phase 2 results were strong and support incremental annual market opportunity of approximately $300K per year. The firm views the results as another potential growth driver and its Outperform rating and $22 price target.
13:40 EDTHZNPHorizon Pharma presents ACTIMMUNE Phase 2 data
Subscribe for More Information
12:04 EDTTGTXTG Therapeutics management to meet with Roth Capital
Subscribe for More Information
October 7, 2014
08:35 EDTEBIOEleven Biotherapeutics granted U.S. composition of matter patent for EBI-005
Eleven Biotherapeutics announced the issuance of U.S. Patent No. 8,853,150 entitled "Chimeric Il-1 Receptor Type I Agonists and Antagonists." This patent covers the composition-of-matter of Eleven’s lead product candidate, EBI-005, a topically-administered interleukin-1 receptor blocker, certain other compositions that are IL-1 receptor antagonists, and related methods for treating ocular surface inflammatory diseases, such as dry eye disease and allergic conjunctivitis. Designed, engineered and generated using Eleven’s AMP-Rx platform, EBI-005 is being developed as a topical protein therapeutic for ocular diseases. Eleven recently reported top-line results of a Phase 2 study of EBI-005 in patients with moderate to severe allergic conjunctivitis and is currently evaluating EBI-005 in a pivotal Phase 3 clinical study in patients with dry eye disease, with top-line data expected in early 2015. “This patent, which will expire in 2031, contains both composition-of-matter and methods of use claims and strengthens our intellectual property portfolio for EBI-005,” said Abbie Celniker, Ph.D., President and CEO. “We were pleased with the recently announced results of our Phase 2 clinical study of EBI-005 in patients with allergic conjunctivitis and look forward to reporting top-line, pivotal Phase 3 data in dry eye disease in early 2015.”
07:29 EDTDRNABernstein to hold a conference
Genes as Drugs Event is being held in New York on October 7.
07:16 EDTDRNABiotech Industry Organization to hold a forum
Subscribe for More Information
07:06 EDTOMEROmeros, Hospira enter into commercial suply agreement for Omidria
Omeros Corporation (OMER) said in a filing that on October 3, it, Hospira S.p.A. and Hospira Worldwide, Inc. (HSP) entered into a Commercial Supply Agreement, pursuant to which Hospira will act as a non-exclusive supplier of Omeros’ product Omidria for commercial sale in the United States and the European Union. Pursuant to the Supply Agreement, Hospira has agreed to manufacture and supply, and Omeros has agreed to purchase, a minimum percentage of Omeros’ requirements of Omidria for commercial sales and clinical supplies for the development of additional therapeutic indications in the United States. In addition, upon receipt of marketing approval in the EU, Hospira has agreed to manufacture and supply a portion of Omeros’ requirements of Omidria in the EU in an amount to be mutually agreed by the parties within four months of marketing approval in Europe, with there being no minimum purchase and supply requirement in the EU if the parties do not reach agreement during such time period and the agreement is not amended thereafter. The Supply Agreement obligates Omeros to provide to Hospira a rolling, non-binding long-term forecast of Omeros’ estimated required quantities of Omidria. The Supply Agreement has an initial term of five years from the date of first commercial sale of Omidria in any country in the Territory. Upon termination of the Supply Agreement, except in the case of termination for an uncured breach by Hospira, Omeros will be required to purchase all of Hospira’s inventory of Omidria and, if applicable, work in progress and reimburse Hospira for all supplies purchased or ordered based on firm purchase orders or Omeros’ estimates of its requirements of Omidria.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use